J&J’s Carvykti and BMS’ Abecma Win FDA Approvals for Earlier Use in Multiple Myeloma
XTalks
APRIL 11, 2024
Concerns of Early Deaths The expanded approvals come after the FDA had flagged reports of early deaths in clinical trials evaluating the therapies in earlier treatment line settings. In last month’s call, Legend CEO Ying Huang, PhD, shared that the partners are aiming to increase manufacturing capacity at their New Jersey plant.
52 
Let's personalize your content